Top

Published in:

01-06-2010 | Review

Targeted therapy for locally advanced renal cell carcinoma

Authors: Eric Jonasch, Nizar M. Tannir

Published in: Targeted Oncology | Issue 2/2010

Abstract

A number of molecularly targeted agents are now available for patients with metastatic renal cell carcinoma. Their role in locally advanced disease is not well defined, and the mechanisms of progression in the high-risk patient are poorly understood. For an agent to be effective in locally advanced renal cell carcinoma it needs to be able to downstage primary tumors, and to prevent the formation of metastases. In this review, we summarize clinical trials assessing the ability of these new agents to cytoreduce primary tumors, and explore available evidence on their ability to prevent the formation of metastases. Ongoing adjuvant clinical trials assessing molecularly targeted agents in the high-risk setting will provide valuable information on their utility in this patient population. Future trials using agents with optimized cytoreductive capabilities in conjunction with therapies capable of preventing metastatic dissemination may improve the outcomes of patients with locally advanced renal cell carcinoma.

Zini L et al (2009) Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer 115(7):1465–1771CrossRefPubMed

Zisman A et al (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19(6):1649–1657PubMed

Escudier B et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134CrossRefPubMed

Escudier B et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111CrossRefPubMed

Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124CrossRefPubMed

Sternberg CN et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068CrossRefPubMed

Hudes G et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281CrossRefPubMed

Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456CrossRefPubMed

Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101(3):297–301PubMed

10.

Patard JJ et al (2004) Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171(6 Pt 1):2181–2185, quiz 2435CrossRefPubMed

11.

Zini L et al (2009) The use of partial nephrectomy in European tertiary care centers. Eur J Surg Oncol 35(6):636–642PubMed

12.

Baillargeon-Gagne S et al (2010) A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma. BJU Int 105(3):359–364CrossRefPubMed

13.

Bex A et al (2002) The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in Situ. Eur Urol 42(6):570–576CrossRefPubMed

14.

Cowey CL et al (2010) Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 28(9):1502–1507CrossRefPubMed

15.

Wood L et al (2009) Sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC). J Clin Oncol 27:15s (abstr 5096)

16.

van der Veldt AA et al (2008) Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res 14(8):2431–2436CrossRefPubMed

17.

Jonasch E et al (2009) Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076–4081CrossRefPubMed

18.

Abel EJ et al (2010) Does targeted therapy result in reliable and meaningful primary tumor downstaging in patients with metastatic renal cell carcinoma? 2010 ASCO Genitourinary Cancers Symposium, San Francisco, abstract 318

19.

Grossman HB et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859–866CrossRefPubMed

20.

Advanced Bladder Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361(9373):1927–1934CrossRef

21.

International collaboration of trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354(9178):533–540CrossRef

22.

Kassouf W et al (2007) P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol 52(3):769–774CrossRefPubMed

23.

Rastogi P et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26(5):778–785CrossRefPubMed

24.

Stephenson AJ et al (2004) Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172(1):58–62CrossRefPubMed

25.

Escudier B et al (2007) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 25(18S):3

26.

Plimack ER et al (2009) Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer 115(9):1859–1866CrossRefPubMed

27.

Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9(4):274–284CrossRefPubMed

28.

Mancuso MR et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116(10):2610–2621CrossRefPubMed

29.

Casanovas O et al (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299–309CrossRefPubMed

30.

Huang D et al (2010) Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 70(3):1053–1062CrossRefPubMed

31.

Ebos JM et al (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232–239CrossRefPubMed

32.

Paez-Ribes M et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220–231CrossRefPubMed

33.

Kim J et al (2009) Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 15(1):81–90CrossRefPubMed

Title: Targeted therapy for locally advanced renal cell carcinoma
Authors: Eric Jonasch
Nizar M. Tannir
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Targeted Oncology / Issue 2/2010
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-010-0147-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Targeted therapies for renal cell carcinoma: understanding their impact on survival

Targeted therapies for non-clear renal cell carcinoma

Emerging molecular classification in renal cell carcinoma: implications for drug development

Prognostic and predictive biomarkers in renal cell carcinoma

Renal cell carcinoma: ten years of significant advances

Perspectives in drug development for metastatic renal cell cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer